Continuity Biosciences reçoit une subvention de 9,6 millions de dollars pour développer un implant à action ultra-longue pour la prévention du VIH

Summary

Continuity Biosciences received a $9.6 million grant to develop an ultra-long-acting subcutaneous implant for HIV prevention, designed to deliver medication over several years from a single insertion. The funding supports development toward IND submission and clinical trial initiation.